Endothelial control of lower limb blood flow in chronic heart failure

David C Lindsay, Diana R Holdright, Debbie Clarke, Inder S Anand, Philip A Poole-Wilson, Peter Collins

Abstract

Background—Limitation of the blood supply to skeletal muscle in chronic heart failure may contribute to the symptoms of fatigue and diminished exercise capacity. The pathophysiology underlying this abnormality is not known. The purpose of this study was to assess the effect of endothelium dependent and independent vasodilator agents on blood flow in the leg of patients with heart failure.

Methods and results—Blood flow in the leg was measured in patients with heart failure (n = 20) and compared with that in patients with ischaemic heart disease and normal left ventricular function (n = 16) and patients with chest pain and normal coronary arteries (n = 8). External iliac artery blood flow was measured using intravascular Doppler ultrasound and quantitative angiography. Flow was recorded at rest and in response to bolus doses of the endothelium independent vasodilator, papaverine. Endothelial dependent responses were measured by infusion of acetylcholine and substance P. Mean (SEM) baseline blood flow was reduced at rest (2.9 (0.4) v 4.5 (0.3) ml/s, P < 0·001) and vascular resistance was raised (37·4 (3·6) v 27·1 (3·0) units, P < 0·05) in patients with heart failure compared with that in controls. The peak blood flow response to papaverine (8 mg), acetylcholine (10⁻⁹–10⁻⁶ mol/l), and substance P (5 pmol/min) was reduced in heart failure, with greater impairment of the response to acetylcholine than substance P. There was a correlation between baseline blood flow in the heart failure group and diuretic dose (r = 0·62, P = 0·003), New York Heart Association classification (r = 0·65, P = 0·002), and left ventricular ejection fraction (r = 0·80, P = 0·0004).

Conclusions—There is reduced blood flow and raised vascular resistance at rest in the legs of patients with heart failure. The degree of impaired blood flow in the leg correlates with the severity of heart failure. There is impairment of the response to both endothelium dependent and independent vasodilators. Abnormal function of the vascular myocyte in heart failure may explain these results as would structural abnormalities of the resistance vessels.

Keywords: endothelium derived relaxing factor; acetylcholine; vasodilatation; congestive heart failure

The commonest symptoms of patients with heart failure are fatigue and shortness of breath. The pathophysiological mechanisms underlying these symptoms are complex, but recent work has emphasised the role of neural and hormonal signals from the periphery. While central haemodynamic variables are important in the genesis of symptoms in acute heart failure, there is poor correlation between the severity of symptoms in chronic heart failure and the left ventricular ejection fraction or pulmonary capillary wedge pressure.¹ ³ Reduction of cardiac output is an important factor limiting exercise capacity when using large groups of muscle, but is unlikely to be a major limiting factor when using small muscle groups. Blood flow to skeletal muscle may increase by 20-fold with exercise. ⁴ This ability to increase limb blood flow with exercise is reduced in patients with chronic heart failure.⁵ ⁶ Flow limitation in the leg and abnormalities of skeletal muscle⁷–⁹ could be the substrate for signals giving rise to the characteristic symptoms of heart failure.¹⁰

The control of limb blood flow is influenced by neural, hormonal, and locally released factors. Endothelium derived relaxing factor (EDRF) contributes to basal peripheral vascular tone in humans in vivo.¹¹ Data from animal models¹²–¹⁶ and humans¹⁵–¹⁷ suggest that the release of EDRF, or the response to its actions, is impaired in chronic heart failure. Most data from humans are derived from studies of forearm vasculature.⁵ ¹¹ Few studies have reported the blood flow response of the leg⁷–¹⁵ despite activities associated with use of the legs being the commonest cause of symptoms.

The aim of the present study was to compare blood flow in the legs of patients with heart failure and those with normal left ventricular function in response to infusion of the endothelium dependent vasodilators, acetylcholine and substance P, and to the endothelium independent agent papaverine. The hypothesis being tested was that the endothelium dependent vasodilator responses of the leg vasculature would be impaired in patients with chronic heart failure.

Patients and methods

STUDY POPULATION

Patients were recruited from those admitted for routine cardiac catheterisation to the Royal
Brompton National Heart & Lung Hospital, London. All were informed of the procedures, and gave their written consent to the study in the presence of an independent witness. The studies were approved by the Ethical Committee of the National Heart & Chest Hospitals.

Patients aged over 18 years undergoing routine cardiac catheterisation were considered for the study. Patients with unstable angina pectoris, severe coronary artery disease, significant valvular stenosis, peripheral vascular disease, diabetes mellitus, asthma, or systemic hypertension (systolic blood pressure > 160 mm Hg or diastolic blood pressure > 100 mm Hg) were excluded. All vasoactive medication (excluding diuretics, digoxin and angiotensin converting enzyme inhibitors) was stopped for a period of at least 16 h before the study.

Patients were characterised as having chronic heart failure on the basis of their clinical history, physical findings, use of diuretic treatment, and left ventricular ejection fraction. Patients were divided into two groups: those with heart failure (group A) and those without heart failure (group B). Two groups of patients were studied as controls in group B: patients with atheromatous coronary artery disease and normal left ventricular function and patients with chest pain and angiographically normal coronary arteries. Patients were not included in the latter group if they had evidence of ST segment change with exercise electrocardiography. Those with chest pain and normal coronary arteries were believed to have non-cardiac chest pain with entirely normal hearts, and thus represent a true control group.

The left ventricular ejection fraction was measured from the left ventricular cineangiogram. The severity of heart failure was assessed by the New York Heart Association classification, dosage of diuretic, left ventricular end diastolic pressure. Exercise capacity was measured in some patients as $MV_{0_2}$ with treadmill exercise testing (ml $O_2$.kg$^{-1}$.min$^{-1}$). The patients with heart failure were subdivided into four groups according to their daily dose of diuretics: no diuretic (group 1); less than or equal to 40 mg frusemide or equivalent (for example, bumetanide 5 mg daily) (group 2); greater than 40 mg frusemide to 80 mg frusemide or its equivalent (for example, bumetanide 1–2 mg daily) (group 3); and greater than 80 mg frusemide or equivalent (group 4).

CATHETER LABORATORY PROTOCOL

Cardiac catheterisation was performed using an eight French gauge sheath in situ in the femoral artery and catheterisation of the right heart was undertaken according to clinical indication. Left ventricular and coronary angiograms were performed using non-ionic x ray contrast medium (Omnipaque; Nycomed AS, Oslo, Norway). Sublingual or systemic nitrates were not administered during the study.

Blood flow velocity was measured using a 20 MHz pulsed wave Doppler catheter positioned in the external iliac artery. The catheters were either Schneider (three French gauge Monoral; Schneider, Zurich, Switzerland) or Wessex (5·5 French gauge, Numed, New York, USA) Doppler catheters. Validation studies in the laboratory showed good correlation between recorded and true flows on an experimental test rig in which there was pulsatile circulation of blood in a closed circuit ($r = 0·98, P < 0·01$).

FEMORAL ARTERIAL ANGIOGRAPHY

Cineangiography of the femoral and external iliac arteries was performed by hand injection of $x$ ray contrast medium (10 ml) and an image was recorded of a radio-opaque calibration marker. The field of view was coned to centre on the external iliac artery and gonadal protection was not used. The external iliac artery diameter was measured at the level of the tip of the catheter using a digital edge detection system (microMipron software; Kontron Elektronik GMBH, Munich, Germany). The artery was assumed to be circular in cross section when calculating vessel area. Sequential angiograms were performed in 22 patients either during, or immediately after administration of each vasoactive agent. Thereafter, the vessel diameter was determined only at the beginning of the study, as it was shown that there were trivial changes of diameter in response to pharmacological interventions (see results).

ADMINISTRATION OF VASODILATOR AGENTS

Vasoactive drugs were delivered through the infusion port of the Doppler catheter using a syringe pump and were continued for 3–5 min. The transit time of infusate through the catheters was 30 s.

**Papaverine**

An ampoule of papaverine (40 mg) (Macarthy Medical, Romford, UK) was diluted to 10 ml with sterile water and aliquots were administered by rapid bolus injection. Three doses of papaverine (4, 8, and 12 mg) were administered in a pilot study to 10 or less patients from each group. No significant increment of flow to the increased doses was found, and therefore a bolus of 8 mg was used for all patients in the main study.

**Acetylcholine**

The desired final concentrations of acetylcholine in the external iliac artery were $10^{-5}$, $10^{-4}$, and $10^{-3}$ mol/l, and the blood flow was assumed to be 200 ml/min to calculate the required dilutions. Ampoules of acetylcholine (20 mg) (Miochol, CooperVision, Southampton, UK) were diluted serially with 5% dextrose immediately before the study. Solutions of $2 \times 10^{-3}$ (0·363 mg/ml), $2 \times 10^{-4}$, and $2 \times 10^{-5}$ mol/l were prepared and infused at 1 ml/min for final presumed concentrations of $10^{-5}$, $10^{-4}$, and $10^{-3}$ mol/l, respectively.

**Substance P and control solution**

There are no previous reports of infusion of substance P into the leg. Three doses of sub-
Endothelial control of lower limb blood flow in chronic heart failure

Results

PATIENT CHARACTERISTICS

Three groups of patients were studied: 20 patients with heart failure (16 men), 16 patients with atheromatous coronary heart disease and normal left ventricular function (12 men), and eight patients with chest pain and normal coronary arteries (five men). None of the latter patients had electrocardiographic changes suggestive of myocardial ischaemia with exercise.

Table 1 shows the baseline characteristics of the patient groups. The aetiology of heart failure was idiopathic dilated cardiomyopathy in eight, ischaemic heart disease in nine, and mitral valve disease in three. The mean (SEM) MVO₂ was 15-6 (1-2) ml o⁻¹kg⁻¹min⁻¹ (n = 9). Mean blood pressure was not significantly different in the two groups of patients without heart failure, but was significantly lower in those with heart failure than those without (88 (4-0) v 99 (2-9) mm Hg, P < 0-05).

Digoxin was taken by 11 patients with heart failure (six with atrial fibrillation) and one each of those with atheromatous coronary heart disease and normal left ventricular function and chest pain and normal coronary arteries, both of whom had atrial fibrillation. Angiotensin converting enzyme inhibitors were taken by 13 patients with heart failure and by none of the other patients. The number of patients with heart failure in each diuretic group was: three (group 1); three (group 2); six (group 3); and eight (group 4). Aspirin was taken by 11 patients with atheromatous coronary heart disease and normal left ventricular function and four with heart failure, but was not used by any of those with chest pain and normal coronary arteries.

VEssel DIameter MEaSUREs

In the initial studies the vessel diameter was measured after each pharmacological intervention in eight patients with chest pain and normal coronary arteries, seven with atheromatous coronary heart disease and normal left ventricular function, and seven with heart failure. Analysis of variance showed that there was no significant change of vessel diameter after each intervention except in response to substance P (5 pmol/min) in patients with chest pain and normal coronary arteries. In the latter patients vessel diameter increased by a

Table 2 Blood flow in the legs of control patients

<table>
<thead>
<tr>
<th>Blood flow (ml/h)</th>
<th>Baseline</th>
<th>Papaverine 8 mg</th>
<th>ACh</th>
<th>Substance P 5 pmol/min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with atheromatous coronary heart disease and normal left ventricular function (n = 16)</td>
<td>43 (0-4)</td>
<td>12-2 (1-4)</td>
<td>11-3 (1-8)</td>
<td></td>
</tr>
<tr>
<td>Patients with chest pain and normal coronary arteries (n = 16)</td>
<td>5-1 (0-7)</td>
<td>13-1 (1-9)</td>
<td>14-9 (4-6)</td>
<td></td>
</tr>
</tbody>
</table>

Values are mean (SEM). There were no significant differences between control groups. ACh, acetycholine.

Table 1 Clinical characteristics of patients

<table>
<thead>
<tr>
<th>Patients with atheromatous coronary heart disease and normal left ventricular function (n = 16)</th>
<th>Patients with chest pain and normal coronary arteries (n = 8)</th>
<th>Patients with heart failure (n = 20)</th>
<th>P value *</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>56-9 (3-0)</td>
<td>52-1 (3-9)</td>
<td>54 (2-6)</td>
</tr>
<tr>
<td>Ejection fraction (%)</td>
<td>68 (4)</td>
<td>78 (2-9)</td>
<td>35 (5-6)</td>
</tr>
<tr>
<td>LVEDP (mm Hg)</td>
<td>11-7 (4-4)</td>
<td>13-5 (4-8)</td>
<td>17-2 (7-1)</td>
</tr>
<tr>
<td>LVEF (g)</td>
<td>76 (3-7)</td>
<td>83 (7-1)</td>
<td>79 (7-6)</td>
</tr>
<tr>
<td>Arterial pressure (mm Hg)</td>
<td>104 (3-5)</td>
<td>94 (4-5)</td>
<td>88 (4-0)</td>
</tr>
</tbody>
</table>
| Values are mean (SEM) (ANOVA). *Patients with versus those without heart failure (i.e. combining patients with atheromatous coronary heart disease and normal left ventricular function and chest pain and normal coronary arteries). LVEDP, left ventricular end diastolic pressure.
Figure 1 Absolute blood flow response to administration of each drug for patients with (n = 20) (■) and without heart failure (n = 24) (□). Bars are group means (SEM). Base, baseline blood flow; P8, papaverine 8 mg; ACh7, ACh6, and ACh5, acetylcholine 10⁻⁷, 10⁻⁶, and 10⁻⁵ mol/l; SP5, substance P 5 pmol/min. *P < 0.05 between the two groups (t test).

DOPPLER FLOW MEASUREMENTS
The baseline blood flow and peak blood flow response to papaverine (8 mg), acetylcholine 10⁻⁷–10⁻⁵ mol/l, and substance P (5 pmol/min) for the control patients are shown in Table 2 and are illustrated for those with and without heart failure in Fig. 1. There was no correlation between baseline blood flow and body weight (*r* = 0.15). Table 3 shows the data derived for the flow ratios (intervention/baseline flow ratio) and increment of flow (ml/s).

Table 3 Increment of blood flow and ratio of flow in the legs of controls and patients with heart failure

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Patients without heart failure (n = 24)</th>
<th>Patients with heart failure (n = 20)</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline blood flow (ml/s)</td>
<td>4.5 (0.3)</td>
<td>2.9 (0.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Increment of flow (ml/s)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papaverine 8 mg ACh</td>
<td>8.0 (0.8)</td>
<td>5.4 (0.8)</td>
<td>0.02</td>
</tr>
<tr>
<td>10⁻³ mol/l</td>
<td>0.7 (0.2)</td>
<td>0.3 (0.2)</td>
<td>0.05</td>
</tr>
<tr>
<td>10⁻⁴ mol/l</td>
<td>3.3 (0.7)</td>
<td>1.9 (0.6)</td>
<td>0.05†</td>
</tr>
<tr>
<td>10⁻⁵ mol/l</td>
<td>8.2 (1.6)</td>
<td>5.4 (1.3)</td>
<td>0.05†</td>
</tr>
<tr>
<td>Substance P 5 pmol/min</td>
<td>4.2 (0.7)</td>
<td>3.1 (0.6)</td>
<td>NS</td>
</tr>
<tr>
<td>Ratio of flow</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papaverine 8 mg ACh</td>
<td>2.7 (0.1)</td>
<td>3.2 (0.3)</td>
<td>NS</td>
</tr>
<tr>
<td>10⁻³ mol/l</td>
<td>1.2 (0.1)</td>
<td>1.2 (0.1)</td>
<td>NS</td>
</tr>
<tr>
<td>10⁻⁴ mol/l</td>
<td>1.8 (0.2)</td>
<td>1.6 (0.2)</td>
<td>NS</td>
</tr>
<tr>
<td>10⁻⁵ mol/l</td>
<td>2.6 (0.2)</td>
<td>2.9 (0.4)</td>
<td>NS</td>
</tr>
<tr>
<td>Substance P 5 pmol/min</td>
<td>1.9 (0.2)</td>
<td>2.1 (0.2)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Values are mean (SEM). *Patients with versus those without heart failure (i.e. combining patients with atheromatous coronary heart disease and normal left ventricular function and chest pain and normal coronary arteries). †P value determined by analysis of variance. ACh, acetylcholine.

Table 4 Vascular resistance in the legs of controls and patients with heart failure

<table>
<thead>
<tr>
<th>Resistance (mm Hg s ml⁻¹)</th>
<th>Patients with atheromatous coronary heart disease and normal left ventricular function (n = 16)</th>
<th>Patients with chest pain and normal coronary arteries (n = 8)</th>
<th>Patients without heart failure (n = 24)*</th>
<th>Patients with heart failure (n = 20)</th>
<th>P value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>29.7 (5.4)</td>
<td>22.9 (5.5)</td>
<td>27.1 (3.0)</td>
<td>37.4 (3.6)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Papaverine 8 mg ACh</td>
<td>11.0 (1.6)</td>
<td>8.9 (2.1)</td>
<td>10.1 (1.3)</td>
<td>14.4 (2.1)</td>
<td>NS</td>
</tr>
<tr>
<td>10⁻³ mol/l</td>
<td>22.9 (2.9)</td>
<td>24.5 (7.6)</td>
<td>22.7 (5.1)</td>
<td>33.3 (3.5)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>10⁻⁴ mol/l</td>
<td>18.9 (3.5)</td>
<td>15.6 (4.4)</td>
<td>17.0 (2.7)</td>
<td>29.5 (4.0)</td>
<td>&lt;0.02</td>
</tr>
<tr>
<td>10⁻⁵ mol/l</td>
<td>14.0 (3.0)</td>
<td>10.6 (3.6)</td>
<td>12.2 (2.4)</td>
<td>17.2 (2.7)</td>
<td>NS</td>
</tr>
<tr>
<td>Substance P 5 pmol/min</td>
<td>14.3 (2.3)</td>
<td>16.3 (5.9)</td>
<td>15.2 (3.2)</td>
<td>19.3 (2.5)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Values are mean (SEM) (ANOVA). *Combining patients with atheromatous coronary heart disease and normal left ventricular function and chest pain and normal coronary arteries. †Patients with versus those without heart failure.

Figure 2 Absolute blood flow response to administration of each drug for patients with heart failure subdivided into "mild" (New York Heart Association (NYHA) III, n = 11) (■) and "severe" (NYHA III/IV, n = 9) (□) groups. Bars are group means (SEM). Abbreviations as given in fig 1. *P < 0.05 (t test).

Figure 3 Correlation of baseline blood flow in the leg with diuretic dose in patients with heart failure. Severity of heart failure was assessed by subdivision into patient groups according to diuretic dose (see text). Group I, no diuretic; group II, ≤ 40 mg frusemide; group III, ≤ 80 mg frusemide; group IV, > 80 mg frusemide (*r* = 0.05, P < 0.005).

Figure 4 Correlation of baseline blood flow in the leg with severity of heart failure. Severity of heart failure was assessed by subdivision into patient groups according to the New York Heart Association (NYHA) classification (*r* = 0.05, P < 0.005).

mental changes (intervention flow minus baseline flow) after each infusion. Analysis of variance showed the presence of heart failure to be a significant determinant of the increment of flow response to acetylcholine (P < 0.005). There was no change in blood pressure with each intervention. Table 4 shows the derived measures of vascular resistance in the leg in response to pharmacological interventions. The absolute flow to each intervention was reduced in patients with more severe heart
 Figure 5 Correlation of baseline blood flow in the leg with left ventricular ejection fraction (LVEF) in patients with heart failure ($r = 0.80$, $P < 0.0005$). Four patients with symptoms and signs of heart failure but with significant mitral regurgitation were excluded from the analysis because of their sparsely increased LVEF (> 60%).

Endothelial control of lower limb blood flow in chronic heart failure (fig 2). There was a correlation between baseline blood flow and diuretic dose (fig 3) ($r = -0.62$, $P = 0.003$) and New York Heart Association classification (fig 4) ($r = -0.65$, $P = 0.002$), but not left ventricular end diastolic pressure ($r = 0.335$, $P = 0.168$) in patients with heart failure. The MVO$_2$ was determined in nine patients with heart failure, but no correlation was found between MVO$_2$ and baseline flow ($r = 0.09$, $P = 0.74$). There was a correlation between baseline blood flow and left ventricular ejection fraction (fig 5) ($r = 0.80$, $P = 0.0004$) when the four patients with heart failure and significant mitral regurgitation were excluded from the analysis (in each case left ventricular ejection fraction > 60%) and no correlation when these patients were included ($r = 0.32$, $P = 0.18$).

Discussion
This study shows that blood flow to the leg is reduced at rest in patients with heart failure compared with that in controls. The absolute flow was reduced in response to administration of papaverine, acetylcholine $10^{-5}$–$10^{-5}$ mol/l, and substance P (5 pmol/min), as was the increment of flow in response to each dose of acetylcholine. There was a significant correlation between the severity of heart failure and absolute flow in response to the vasodilator agents.

The dominant symptoms of heart failure are those of fatigue and breathlessness. These symptoms correlate poorly with simple haemodynamic variables, such as left ventricular ejection fraction and pulmonary capillary wedge pressure. $^1$–$^3$ and abnormalities in the peripheral vasculature in heart failure$^4$–$^9$ may be important in the genesis of these symptoms. The control of peripheral vascular resistance lies predominantly in the resistance arterioles and is determined by functional or structural changes of the vessel wall, or both. $^{10}$ Vasomotor tone is determined by the effects of neurological stimuli (e.g. the release of norepinephrine and neuropeptides), endocrine stimuli (e.g. angiotensin II or circulating norepinephrine), and locally released paracrine substances, such as endothelium derived relaxing and contracting factors. The sympathetic nervous system is activated in chronic heart failure, although acute administration of adrenergic blocking drugs into the femoral artery does not increase blood flow in the leg.$^6$ $^7$ EDRF has been found to be important in the maintenance of vascular tone in vivo.$^8$ $^9$

Our findings are not wholly in agreement with those from other authors. We have shown impairment of the vasodilator response to both endothelium dependent (acetylcholine and substance P) and independent agents (papaverine) in patients with heart failure, and this impaired flow response correlates with the severity of heart failure. The study of blood flow in the leg, rather than the arm, is of particular relevance as the reduction of exercise induced blood flow in the leg is a limiting factor to exercise capacity in patients with heart failure.$^5$ Only one previous study has examined the response of the leg to endothelium dependent and independent vasodilator agents.$^5$ This study by Katz et al$^{11}$ assessed blood flow in the leg semiquantitatively by transcutaneous Doppler measurement of flow velocity in the superficial femoral artery. No formal comparison was made of basal flow velocity at rest in controls and patients with heart failure, although it seemed marginally reduced in patients with heart failure. The increase in flow velocity to administration of intra-arterial acetylcholine was significantly reduced, and there was blunting of the response to glyceryl trinitrate.

Other studies of peripheral blood flow to skeletal muscle in heart failure have measured blood flow in the forearm using venous occlusive plethysmography$^{10}$ or transcutaneous Doppler ultrasonography.$^{11}$ In the former study there was significant reduction of methacholine induced vasodilatation, and in the latter of the response to acetylcholine. In contrast to the present study, there was no impairment of the response to endothelium independent actions of nitroprusside or glyceryl trinitrate, respectively. It is not clear whether preservation of response to endothelium independent agents in these two studies reflects differences in vascular tone between the arm and leg, as there may be regional differences of vasomotor control in patients with heart failure.$^{12}$

Maximal vasodilatation cannot be achieved safely in vivo by pharmacological means, and maximum blood flow achieved in these studies is considerably less than may be attained during peak exercise in a normal individual.$^4$ Papaverine is probably an endothelium independent vasodilator in vivo in humans and has been shown to be a powerful vasodilator of the coronary circulation.$^{13}$ The drug is administered in bolus form, but its use is limited by the occurrence of arrhythmias at high doses. Many previous investigators have used only acetylcholine or methacholine as endothelium dependent vasodilators.$^{14}$ $^{16}$ Acetylcholine has vasodilator properties mediated through muscarinic receptor activated release of EDRF and has muscarinic-vasoconstrictor properties through its direct actions on vascular smooth muscle. The vasoconstrictor actions occur at high concentrations of $10^{-5}$ mol/l and above, but altered sensitivity of the muscarinic receptor may exist in heart failure$^{17}$ $^{27}$ and has been.
shown in a dog model of heart failure.39 The use of substance P in these experiments allowed more specific determination of the role of EDRF in the control of vasomotor tone in heart failure. Substance P has a direct effect on the release of EDRF and has no direct effects on vascular smooth muscle.40

It is not possible from the present study to determine the mechanisms underlying impaired endothelium dependent responses in heart failure. The study of blood flow in the forearms by Drexler et al41 is of interest as a specific inhibitor of EDRF, Nω-monomethyl-L-arginine, was infused locally into the brachial artery. Infusion of this inhibitor produced an exaggerated decrease in brachial arterial flow in patients with heart failure, suggesting that basal release of EDRF is preserved or even enhanced in patients with heart failure.

Atherosclerosis of any severity may cause impairment of endothelial function40 42 and it was for this reason patients with heart failure of ischaemic and non-ischaemic aetiology and a control group of similar individuals with or without demonstrable atheromatous coronary artery disease were studied. Patients with chest pain, angiographically normal coronary arteries, and ST segment change with exercise electrocardiography (often termed “syndrome X’) were excluded, as it has been suggested that these patients may have widespread abnormalities of vasomotor control.43 Hypertension,44 45 hypercholesterolaemia,46 47 and diabetes mellitus,48 have been implicated in the genesis of vasomotor dysfunction.

There is no optimal method of representing changes of blood flow in such studies. Results are sometimes presented as absolute blood flows, but more often as the increment of increased blood flow above baseline value, the percentage change, or as a ratio of peak flow to baseline blood flow. Such representation can be misleading in assessing the degree of abnormality of vasomotor control if the baseline blood flow is significantly different in the two groups, as was the case in the present study.

Some effects of angiotensin converting enzyme inhibitors, captopril, has been reported to increase endothelium dependent vasodilatation in patients with essential hypertension.49 Digitalis glycosides may inhibit the release of EDRF and the response of vascular smooth muscle to its actions.50 Aspirin was taken by most patients with atheromatous coronary heart disease and normal left ventricular function. The effects of cyclo-oxygenase inhibition on blood flow responses have not been determined fully, although it has been reported that aspirin may reduce the vasodilator properties of the angiotensin converting enzyme inhibitor, enalapril.51

Blood flow in the external iliac artery in each individual was not known before the investigation, and thus an assumed blood flow of 200 ml/min was used to calculate the required dilution of each drug. The data from the literature suggest flows of 290–420 ml/min in normal controls46 47 and 210–310 ml/min in patients with heart failure.6 44 45 These measurements were made by various techniques, at differing levels in the external iliac or femoral arteries, and in patients with heart failure of varying severity. The flows observed in the present study were within this range, so that the actual drug concentration was close to the expected concentration. The lesser baseline blood flow in the external iliac artery of patients with heart failure will have led to higher concentrations of vasodilator agents and will therefore have underestimated the degree of impairment of vasodilator response.

Increased blood flow may itself cause reflex vasodilatation of the large arteries mediated by the shear stress induced release of EDRF.46 The compliance of the brachial artery is reduced in patients with heart failure.49 The change of external iliac artery diameter in this study was minimal, and angiograms were therefore not performed after each intervention. The changes in blood flow shown in this study must therefore be the result of changes in the microcirculation.

There was no significant difference in body weight between the controls and patients with heart failure. There was no correlation between body weight and baseline flow in the leg, although no specific measurement of leg or skeletal muscle mass was made. Muscle wasting may occur in patients with heart failure, and a reduction of leg muscle mass might account in part for the reduced blood flow and increased resistance noted in our study.

The cause of increased peripheral vascular resistance in heart failure is not known. The retention of sodium and water in oedematous heart failure may increase vascular tone and diminish vasodilator reserve, possibly through activation of a sodium-calciun exchange mechanism47 48 in an endothelial independent manner. Plasma endothelin levels are increased in chronic heart failure,50 as are levels of tumour necrosis factor,51 and other cytokines, several of which influence vascular tone by endothelium dependent and independent effects.41 Furthermore, disturbance of prostaglandin levels has been reported in chronic heart failure and may impair control of vasomotor tone.52 53 The reduced vasodilator response to exercise in heart failure may be due to a reduced response to local metabolites.

LIMITATIONS OF THE STUDY
Medication, apart from angiotensin converting enzyme inhibitors, digoxin or diuretic treatment, was stopped for at least 16 h before the study, although the longer term effects of such treatment are not known. The theoretical concerns about changes of external iliac artery diameter in response to increased flow were not supported by our data. The determination of blood flow in patients with atrial fibrillation is problematic, although measurement of mean blood flow minimises any beat to beat variation. The optimum method of displaying

Lindsay, Holdright, Clarke, Anand, Poole-Wilson, Collins
and comparing flow after administration of vasoactive drugs is not clear, particularly if the baseline flow is different in the groups, as in this study. No significant difference existed when comparing ratios or increments of flow, but it is likely that the absolute flow is the most important physiological determinant.

Conclusions

The study fails to show derangement of vasoconstrictor control in the vasculature of the leg in patients with chronic heart failure. Evidence has been presented for impairment of the response to endothelium dependent (acetylcholine and substance P) and independent (papaverine) agents. The underlying cause for these abnormalities has not been elicited, although structural factors in the resistance vessels may be important. A correlation has been shown between the severity of the heart failure and impaired flow in the leg. These data confirm the importance of peripheral abnormalities in the pathophysiology of chronic heart failure and suggest possible mechanisms for the genesis of symptoms in this condition.

We are indebted to the patients who participated in this study, Sister G Maketo, the catheter laboratory staff, P Allibone, S Pearson, and the staff on Paul Wood and York wards at the Royal Brompton National Heart & Lung Hospital without whose help and cooperation this study would not have been possible. We would also thank Dr Ghazi for his assistance in assigning substance P. DCL is supported by a junior research fellowship from the British Heart Foundation and DRH by a Brussels-Myers Squibb cardiovascular fellowship.

ABSTRACTS IN CARDIOLOGY

Need you biopsy for acute myocarditis?

The Mason trial of treating acute myocarditis has appeared. One of the most significant results is that at most 10% of subjects with clinically suspected acute myocarditis will have a positive tissue confirmation. Because a positive tissue diagnosis was an entry criteria the trial turned out rather smaller than hoped.

Nevertheless there is nothing to suggest that immunosuppression is beneficial. The implication is that cardiac biopsy if carried out with the sole aim of establishing a diagnosis to aid treatment is not a useful procedure. Numerous questions remain. What disease is present and what is the prognosis of those patients with a negative biopsy?

M J DAVIES

A clinical trial of immunosuppressive therapy for myocarditis

Jay W Mason, John B O'Connell, Ainhoa Hershovits, Noel R Rose, Bruce M McManus, Margaret E Billingham, Thomas E Moon, The Myocarditis Treatment Trial Investigators

Background—Myocarditis is a serious disorder, and treatment options are limited. This trial was designed to determine whether immunosuppressive therapy improves left ventricular function in patients with myocarditis.

Methods—We randomly assigned 111 patients with a histopathological diagnosis of myocarditis and a left ventricular ejection fraction of less than 0.45 to receive conventional therapy alone or combined with a 24-week regimen of immunosuppressive therapy. Immunosuppressive therapy consisted of prednisone with either cyclosporine or azathioprine. The primary outcome measure was a change in the left ventricular ejection fraction at 28 weeks.

Results—In the group as a whole, the mean (± SE) left ventricular ejection fraction improved from 0.25 ± 0.01 at base line to 0.34 ± 0.02 at 28 weeks (P < 0.001). The mean change in the left ventricular ejection fraction at 28 weeks did not differ significantly between the group of patients who received immunosuppressive therapy (a gain of 0.10; 95 percent confidence interval, 0.07 to 0.12) and the control group (a gain of 0.07; 95 percent confidence interval, 0.03 to 0.12). A higher left ventricular ejection fraction at base line, less intensive conventional drug therapy at base line, and a shorter duration of disease, but not the treatment assignment, were positive independent predictors of the left ventricular ejection fraction at week 28. There was no significant difference in survival between the two groups (P = 0.96). The mortality rate for the entire group was 20 percent at 1 year and 56 percent at 4.3 years. Features suggesting an effective inflammatory response were associated with less severe initial disease.

Conclusions—Our results do not support routine treatment of myocarditis with immunosuppressive drugs. Ventricular function improved regardless of whether patients received immunosuppressive therapy, but long-term mortality was high. (N Engl J Med 1995;333:269-75.)
Endothelial control of lower limb blood flow in chronic heart failure.

D. C. Lindsay, D. R. Holdright, D. Clarke, I. S. Anand, P. A. Poole-Wilson and P. Collins

*Heart* 1996 75: 469-476
doi: 10.1136/hrt.75.5.469